Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Unknown 1Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Prostatic Neoplasms 1Precancerous Conditions 1Kidney Neoplasms 1Esophageal Neoplasms 1Carcinoma, Renal Cell 1Breast Neoplasms 1Barrett Esophagus 1Adenocarcinoma Of Esophagus 1

Interventions

Cyclophosphamide 77Docetaxel 69Capecitabine 64Trastuzumab 61Paclitaxel 50Tamoxifen 47Epirubicin 47Letrozole 44pyrotinib 40Fulvestrant 37Doxorubicin 35Vinorelbine 33Radiotherapy 32Carboplatin 32Anastrozole 28exemestane 27Neoadjuvant Therapy 24Drug Therapy 22Fluorouracil 21palbociclib 20Exercise 20Chemotherapy, Adjuvant 19Bevacizumab 18pertuzumab 16Goserelin 16Cisplatin 16liposomal doxorubicin 15Mammography 14Gemcitabine 14Blood Specimen Collection 14

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Breast Neoplasms × Comparative Genomic Hybridization × Clear all
NCT00070278 2013-08-07

Neoadjuvant Epirubicin, Cyclophosphamide, and Paclitaxel With or Without Gemcitabine in Treating Women Who Are Undergoing Surgery for Early Breast Cancer

National Cancer Institute (NCI)

Phase 3 Unknown
800 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡